Search

Your search keyword '"Cholesterol, LDL drug effects"' showing total 18 results
Start Over Descriptor "Cholesterol, LDL drug effects" Publication Type Magazines
18 results on '"Cholesterol, LDL drug effects"'

1. PCSK9-lowering RNAi contender clears first phase III trial.

Author

Mullard A

Subjects
Clinical Trials, Phase III as Topic, Heart Diseases genetics, Humans, Proprotein Convertase 9 genetics, Anticholesteremic Agents therapeutic use, Cholesterol, LDL drug effects, Heart Diseases prevention & control, PCSK9 Inhibitors, RNA Interference, RNA, Small Interfering therapeutic use
Published
2019
Full Text
View/download PDF

2. Evolocumab approved for reducing LDL cholesterol.

Author

Traynor K

Subjects
Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents administration & dosage, Anticholesteremic Agents adverse effects, Cholesterol, LDL drug effects, Drug Approval, Humans, Hyperlipoproteinemia Type II drug therapy, United States, United States Food and Drug Administration, Antibodies, Monoclonal therapeutic use, Anticholesteremic Agents therapeutic use, Hypercholesterolemia drug therapy
Published
2015
Full Text
View/download PDF

3. [Hypercholesterolemia: Monoclonal antibodies safe and effective].

Author

Windler E

Subjects
Antibodies, Monoclonal, Humanized, Cholesterol, LDL drug effects, Cholesterol, LDL metabolism, Humans, Hypercholesterolemia metabolism, Proprotein Convertase 9, Antibodies, Monoclonal therapeutic use, Hypercholesterolemia drug therapy, Proprotein Convertases therapeutic use, Serine Endopeptidases therapeutic use
Published
2015
Full Text
View/download PDF

4. Statins help more than harm those at risk of diabetes.

Subjects
Cholesterol, LDL drug effects, Diabetes Mellitus prevention & control, Dose-Response Relationship, Drug, Humans, Hypercholesterolemia etiology, Cardiovascular Diseases prevention & control, Diabetes Complications drug therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypercholesterolemia prevention & control, Risk Reduction Behavior
Published
2014

5. Some question use of statins to reduce cardiovascular risks in healthy women.

Author

Mitka M

Subjects
Cardiovascular Diseases mortality, Cholesterol, LDL drug effects, Diabetes Mellitus epidemiology, Female, Humans, Male, Meta-Analysis as Topic, Postmenopause, Practice Guidelines as Topic, Risk, Sex Factors, Cardiovascular Diseases prevention & control, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Primary Prevention
Published
2012
Full Text
View/download PDF

6. Researchers still seek clinical benefit in raising levels of good cholesterol.

Author

Mitka M

Subjects
Cholesterol, LDL drug effects, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Niacin pharmacology, Randomized Controlled Trials as Topic, Risk, Simvastatin therapeutic use, Cardiovascular Diseases prevention & control, Cholesterol Ester Transfer Proteins antagonists & inhibitors, Cholesterol, HDL blood, Cholesterol, HDL drug effects
Published
2012
Full Text
View/download PDF

7. Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit.

Author

Mitka M

Subjects
Azetidines, Cardiovascular Diseases epidemiology, Carotid Arteries diagnostic imaging, Carotid Arteries pathology, Clinical Trials as Topic, Drug Approval, Ezetimibe, Humans, Hypolipidemic Agents administration & dosage, Niacin administration & dosage, Practice Patterns, Physicians' statistics & numerical data, Risk Factors, Simvastatin therapeutic use, Treatment Outcome, Ultrasonography, United States, United States Food and Drug Administration, Anticholesteremic Agents therapeutic use, Cardiovascular Diseases prevention & control, Cholesterol, LDL drug effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypercholesterolemia drug therapy
Published
2010
Full Text
View/download PDF

9. New vitamin helps lower cholesterol.

Subjects
Cholesterol, LDL drug effects, Humans, Cholesterol, Dietary Supplements, Hypercholesterolemia prevention & control, Phytosterols therapeutic use, Vitamins therapeutic use
Published
2008

10. High-dose atorvastatin therapy achieves 25% reduction in CV events in TNT substudy of diabetic patients.

Subjects
Atorvastatin, Cholesterol, HDL blood, Cholesterol, HDL drug effects, Cholesterol, LDL blood, Cholesterol, LDL drug effects, Coronary Disease blood, Coronary Disease epidemiology, Coronary Disease etiology, Diabetes Mellitus, Type 2 blood, Dose-Response Relationship, Drug, Dyslipidemias blood, Dyslipidemias complications, Dyslipidemias epidemiology, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Risk Factors, Triglycerides blood, Anticholesteremic Agents administration & dosage, Coronary Disease prevention & control, Diabetes Mellitus, Type 2 complications, Dyslipidemias drug therapy, Heptanoic Acids administration & dosage, Pyrroles administration & dosage
Published
2006

11. [Pronounced lowering of low density cholesterol combined with elevation of high density cholesterol was associated with reduction of coronary atheroma. Results of ASTEROID trial].

Author

Gratsianskiĭ NA

Subjects
Cholesterol, HDL drug effects, Cholesterol, LDL drug effects, Clinical Trials as Topic, Congresses as Topic, Coronary Artery Disease drug therapy, Fluorobenzenes therapeutic use, Humans, Pyrimidines therapeutic use, Rosuvastatin Calcium, Sulfonamides therapeutic use, Cholesterol, HDL blood, Cholesterol, LDL blood, Coronary Artery Disease blood, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Published
2006

12. Ezetimibe offers new opportunity to lower LDL-C to target levels.

Subjects
C-Reactive Protein drug effects, C-Reactive Protein metabolism, Drug Therapy, Combination, Dyslipidemias blood, Ezetimibe, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, South Africa epidemiology, Vascular Diseases blood, Vascular Diseases drug therapy, Anticholesteremic Agents therapeutic use, Azetidines therapeutic use, Cholesterol, LDL blood, Cholesterol, LDL drug effects, Dyslipidemias drug therapy
Published
2005

13. Plaque composition changes on rosuvastatin treatment.

Subjects
Biomarkers blood, Carotid Artery, Common metabolism, Carotid Artery, Common pathology, Carotid Stenosis metabolism, Cholesterol, LDL drug effects, Cholesterol, LDL metabolism, Dose-Response Relationship, Drug, Humans, Rosuvastatin Calcium, Carotid Stenosis drug therapy, Fluorobenzenes administration & dosage, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Pyrimidines administration & dosage, Sulfonamides administration & dosage
Published
2005

14. Study suggests statins for diabetics with healthy LDL cholesterol levels.

Author

Rollins G

Subjects
Aged, Cardiovascular Diseases drug therapy, Cardiovascular Diseases mortality, Diabetes Mellitus, Type 2 mortality, Humans, Middle Aged, Practice Guidelines as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Triglycerides, Anticholesteremic Agents therapeutic use, Cardiovascular Diseases prevention & control, Cholesterol, LDL drug effects, Diabetes Mellitus, Type 2 drug therapy, Heptanoic Acids therapeutic use, Pyrroles therapeutic use
Published
2004

16. LDL cholesterol goals rapidly achieved at various starting doses of Pfizer's atorvastatin.

Subjects
Atorvastatin, Cholesterol, LDL blood, Cholinergic Antagonists pharmacology, Clinical Trials as Topic, Dose-Response Relationship, Drug, Heptanoic Acids pharmacology, Humans, Pyrroles pharmacology, Cholesterol, LDL drug effects, Cholinergic Antagonists therapeutic use, Heptanoic Acids therapeutic use, Hypercholesterolemia drug therapy, Pyrroles therapeutic use
Published
2004

17. Zeroing in on how low cholesterol should go.

Subjects
Atorvastatin, Heptanoic Acids administration & dosage, Humans, Pravastatin administration & dosage, Pyrroles administration & dosage, Risk Factors, Anticholesteremic Agents administration & dosage, Arteriosclerosis prevention & control, Cholesterol, LDL drug effects
Published
2002

18. Raloxifene: magic bullet for heart and bone?

Author

Gustafsson JA

Subjects
Cholesterol, LDL blood, Cholesterol, LDL drug effects, Clinical Trials as Topic, Estradiol pharmacology, Estrogen Antagonists therapeutic use, Estrogens physiology, Female, Humans, Piperidines metabolism, Piperidines therapeutic use, Raloxifene Hydrochloride, Receptors, Estrogen chemistry, Receptors, Estrogen physiology, Bone and Bones drug effects, Estrogen Antagonists pharmacology, Piperidines pharmacology, Postmenopause
Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results